DEEP PATEL: Open Payments
NPI 1194247072 · RIVERSIDE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,140 in 102 payments from 14 companies in 2025. Trend: 2023 $1,515 · 2024 $1,912 · 2025 $2,140
Food & beverage: $2,017Education: $123
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 29 | $587 |
| E.R. Squibb & Sons, L.L.C. | 18 | $363 |
| Teva Pharmaceuticals USA, Inc. | 16 | $311 |
| Vanda Pharmaceuticals Inc. | 8 | $221 |
| Otsuka America Pharmaceutical, Inc. | 10 | $214 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $106 |
| Janssen Pharmaceuticals, Inc | 4 | $105 |
| Lundbeck LLC | 4 | $86 |
| ABBVIE INC. | 2 | $37 |
| Supernus Pharmaceuticals, Inc. | 2 | $35 |
Products named: INGREZZA, COBENFY, REXULTI, FANAPT, UZEDY, CAPLYTA, SPRAVATO, AUSTEDO XR.
Industry payments across CA — which companies pay providers there.
